Circulating high sensitivity troponin T in severe sepsis and septic shock: distribution, associated factors, and relation to outcome by Røsjø, Helge et al.
Helge Røsjø
Marjut Varpula
Tor-Arne Hagve
Sari Karlsson
Esko Ruokonen
Ville Pettila ¨
Torbjørn Omland
The FINNSEPSIS Study Group
Circulating high sensitivity troponin T in severe
sepsis and septic shock: distribution,
associated factors, and relation to outcome
Received: 27 January 2010
Accepted: 3 August 2010
Published online: 12 October 2010
 The Author(s) 2010. This article is
published with open access at
Springerlink.com
On behalf of the FINNSEPSIS Study Group.
A complete list of the investigators who
participated in the study is presented in
‘‘Appendix 1’’.
Electronic supplementary material
The online version of this article
(doi:10.1007/s00134-010-2051-x) contains
supplementary material, which is available
to authorized users.
H. Røsjø  T. Omland ())
Division of Medicine, Akershus University
Hospital, Sykehusveien 27, 1478
Lørenskog, Norway
e-mail: torbjorn.omland@medisin.uio.no
Tel.: ?47-91-502900
Fax: ?47-67-962190
H. Røsjø  T. Omland
Institute of Clinical Medicine,
University of Oslo, Oslo, Norway
H. Røsjø  T. Omland
Center for Heart Failure Research,
University of Oslo, Oslo, Norway
M. Varpula  V. Pettila ¨  The FINNSEPSIS
Study Group
Division of Anesthesiology and Intensive
Care Medicine, Department of Surgery,
Helsinki University Hospital, Helsinki,
Finland
T.-A. Hagve
Center of Laboratory Medicine,
Akershus University Hospital,
Lørenskog, Norway
S. Karlsson
Department of Anesthesiology
and Intensive Care, Tampere
University Hospital, Tampere, Finland
E. Ruokonen
Department of Anesthesiology and
Intensive Care, Kuopio University Hospital,
Kuopio, Finland
Abstract Purpose: To assess the
clinical utility of a recently developed
highly sensitive cardiac troponin T
(hs-cTnT) assay for providing prog-
nostic information on patients with
sepsis. Methods: cTnT levels were
measured by the novel hs-cTnT assay
at two time points (inclusion and 72 h
thereafter) in a subgroup of patients
from the FINNSEPSIS study and
associations with clinical outcomes
were examined. Results for the hs-
cTnT assay were compared to those
of the established fourth-generation
cTnT assay. Results: cTnT mea-
sured by the fourth-generation and hs-
cTnT assay was detectable in 124
(60%) and 207 (100%) patients,
respectively, on inclusion in this
study. hs-cTnT levels on inclusion
correlated with several indices of risk
in sepsis, including the simpliﬁed
acute physiology score (SAPS) II and
sequential organ failure assessment
(SOFA) scores. The level of hs-cTnT
on inclusion was higher in hospital
non-survivors (n = 47) than survi-
vors (n = 160) (median 0.054 [Q1–3,
0.022–0.227] versus 0.035
[0.015–0.111] lg/L, P = 0.047), but
hs-cTnT level was not an independent
predictor of in-hospital mortality. hs-
cTnT levels on inclusion were also
higher in patients with septic shock
during the hospitalization (0.044
[0.024–0.171] versus 0.033
[0.012–0.103] lg/L, P = 0.03), while
this was not the case for the fourth-
generation cTnT assay or NT-proB-
NP levels. Conclusions: Circulating
hs-cTnT is present in patients with
severe sepsis and septic shock, asso-
ciates with disease severity and
survival, but does not add to SAPS II
score for prediction of mortality. hs-
cTnT measurement could still have a
role in sepsis as an early marker of
shock.
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Severe sepsis and septic shock are commonly complicated
by myocardial dysfunction, even in patients without pre-
existing coronary artery disease [1, 2], and cardiac failure
may contribute to poor outcome in these patients [1, 2].
Early recognition of myocardial injury and ventricular
dysfunction in severe sepsis and septic shock may
improve short-term prognosis, but is difﬁcult to diagnose
[3].
Cardiac troponins T (cTnT) and I (cTnI) are compo-
nents of the myoﬁbrillar contractile apparatus of
cardiomyocytes. Measurement of troponins is routinely
used for diagnosis of myocardial necrosis in patients with
suspected acute coronary syndromes [4, 5], and to identify
patients beneﬁting from early medical and coronary
interventions [6, 7]. Recently, several studies have also
reported detectable cTnT or cTnI levels in patients with
sepsis, but their predictive value has not been ﬁrmly
established [8–16]. Explanations for the diverging results
regarding utility of troponin testing in sepsis may be
inadequate sample size and use of troponin assays with
limited sensitivity and precision in the low concentration
range [8–16]. However, a new and highly sensitive assay
for cTnT (hs-cTnT) measurement now allows detection of
concentrations tenfold lower than with previous assays
[17]. The clinical beneﬁt of using this novel hs-cTnT
assay has been demonstrated in patients with stable cor-
onary artery disease and preserved left ventricular
function, as the hs-cTnT assay detected measurable levels
of troponin T in 97.7% of these patients, and improved
risk stratiﬁcation beyond standard patient evaluation [18].
In contrast, only 1.3% of these patients would have had
measurable levels of cTnT with the conventional fourth-
generation assay.
Accordingly, we hypothesized that hs-cTnT would be
detectable in a high proportion of patients with sepsis or
septic shock, be associated with conventional risk mark-
ers in sepsis, and provide superior prognostic information
compared to a conventional fourth-generation cTnT
assay.
Materials and methods
Study design
The study is a substudy of FINNSEPSIS, a prospective
observational cohort study of the incidence and prognosis
of sepsis in 24 intensive care units (ICUs) in Finland [19,
20]. In brief, all patients aged 18 years or older admitted
to the ICUs of participating centres were screened daily
for the American College of Chest Physicians/Society of
Critical Care Medicine criteria of severe sepsis or septic
shock. All patients fulﬁlling the criteria, i.e. known or
suspected infection, with two or more criteria for systemic
inﬂammatory response syndrome, and at least one new,
sepsis-induced organ failure, were included in the
FINNSEPSIS cohort. Previous diagnosis of cardiovascu-
lar disease (deﬁned as either a history of heart failure or
coronary artery disease requiring medication or former
disease-associated procedure), hypertension, or diabetes
mellitus was collected from patient chart records. Peak
creatinine and lactate levels, the lowest platelet count, and
maximal dose of vasoactive drugs infused during the ﬁrst
24 h after inclusion were also recorded. After the ﬁrst
24 h, the simpliﬁed acute physiology score (SAPS) II was
recorded [21]. The sequential organ failure assessment
(SOFA) was subsequently scored daily [22]. All data were
collected and transferred via internet to the Finnish
intensive care quality consortium (Intensium, Kuopio,
Finland). In-hospital mortality was recorded and classiﬁed
as the primary endpoint. Patients were screened daily for
septicshockduringtheICUstay,andshockwasconsidered
a secondary endpoint. The FINNSEPSIS study and all
substudies have been approved by the Regional Ethics
Committees at each participating centre, and the study was
performed according to the Declaration of Helsinki.
Biochemical analyses
For this biomarker substudy, patients were included if
written informed consent for blood sampling could be
obtained from the patient or a relative, and if laboratory
samples were available from both inclusion in the
study and 72 h thereafter (Fig. 1). Blood sampling was
Fig. 1 Flow chart for the study
78performed from indwelling arterial catheters or by veni-
puncture [23, 24]. The samples were centrifuged at room
temperature and the serum component was aspirated and
frozen at -20C at individual centres. Within 3 months of
collection, plasma samples were shipped on dry ice to
the Helsinki University Hospital for storage at -80C
for 4 years pending analysis at Akershus University
Hospital.
hs-cTnT and cTnT levels were determined on an
autoanalyzer (Cobas e 411) using only commercial assays
(Roche Diagnostics, Penzberg, Germany). The hs-cTnT
assay utilizes the same antibodies as the conventional
fourth-generation assay [17]. The lower detection level of
the hs-cTnT assay is 0.003 lg/L, and the 99th percentile
value with less than 10% coefﬁcient of variance (CV) in
healthy subjects is 0.014 lg/L. The corresponding
detection limit for the fourth-generation assay is 0.01 lg/
L, and the 99th percentile value with less than 10% CV is
0.03 lg/L. The laboratory personnel were blinded to
patients clinical information.
Estimated glomerulal ﬁltration rate (eGFR) was cal-
culated by the MDRD formula [25], N-terminal pro-
B-type natriuretic peptide (NT-proBNP) was analysed as
previously described [24], and body mass index (BMI)
was calculated as weight (kg)/height (m)
2.
Statistical analyses
Data are presented as median (quartile (Q) 1–3) or
absolute values and percentages. We assessed differences
between groups by the Mann–Whitney U test for con-
tinuous variables as most were not normally distributed,
while categorical data were compared by the Fisher exact
test. Associations between variables were assessed by
Spearman rank correlation. Variables associated with hs-
TnT levels (logarithmic transformation) on inclusion were
evaluated by multivariate linear regression analysis with
age, gender, previous cardiovascular disease, hyperten-
sion, diabetes, BMI, NT-proBNP, eGFR, and peak lactate
levels and lowest platelet count within the ﬁrst 24 h from
inclusion in the model (logarithmic transformation for the
last four variables). Odds ratios (OR) with 95% conﬁ-
dence interval (CI) for in-hospital mortality were
calculated by logistic regression analysis. Because of
skewed distributions, troponin T measurements were
entered after logarithmic transformation. Predictive fac-
tors that were signiﬁcant in univariate analysis were
included in a multivariate model using a forward selection
procedure. Receiver operating characteristics (ROC)
curve analysis was used for identiﬁcation of optimal cut-
off points and to examine discrimination, and areas under
the curve (AUCs with 95% CI) were compared [26].
P values less than 0.05 were considered signiﬁcant for all
analyses. Statistical analyses were performed with SPSS
for Windows version 14.0 (SPSS, Chicago, IL) with the
exception of the comparison of ROC AUCs, which was
performed with MedCalc for Windows, version 9.5.1.0
(MedCalc Software, Mariakerke, Belgium) and the sta-
tistical programming language R (R Development Core
Team, 2008).
Results
Patient characteristics
We included all patients who gave written informed
consent and for whom blood samples were available at
both time points examined: (1) inclusion in this study and
(2) 72 h thereafter. This accounted for 207 out of the 470
patients (44%) from the FINNSEPSIS cohort (Fig. 1).
Median duration from diagnosis of sepsis to blood sam-
pling was 9 h (Q1–3, 3–17 h). Of these 207 patients, 47
(23%) died in the hospital. Characteristics of the patients
according to in-hospital mortality are summarized in
Table 1.
Cardiac-speciﬁc troponins
cTnT measured by the fourth-generation assay was not
detectable in 83 (40%) of the patients on inclusion in the
study, while 87 patients (43%) had undetectable levels
72 h after inclusion. In contrast, cTnT measured by the
highly sensitive assay was detectable in all patients at
both time points. On inclusion, hs-cTnT levels ranged
from 0.004 to 13.577 lg/L (median 0.039 lg/L [Q1–3,
0.017–0.135 lg/L]), whereas after 72 h concentrations
ranged from 0.003 to 6.580 lg/L (median 0.037 lg/L
[Q1–3, 0.016–0.109 lg/L]). Median cTnT levels mea-
sured by the fourth-generation assay were 0.02 lg/L at
both time points (Q1–3, 0.00–0.11 and 0.00–0.09 lg/L,
respectively). On inclusion, 166 patients (80%) had cTnT
levels over the normal 99th percentile value according to
the hs-cTnT assay ([0.014 lg/L) versus 86 patients
(42%) according to the fourth-generation cTnT assay
([0.03 lg/L) (Supplementary Figure). Similarly, hs-cTnT
levels were elevated in 161 patients (of 204, 79%) 72 h
after inclusion compared to 14 patients (7%) according to
the fourth-generation assay (Supplementary Figure).
Characteristics of the patients according to hs-cTnT ele-
vation on inclusion in this study are shown in the online
supplementary material (Supplementary Table 1).
A correlation was observed between hs-cTnT levels on
inclusion and after 72 h (n = 204; r = 0.82, P\0.001).
hs-cTnT levels on inclusion were also correlated with
severity of disease (SAPS II score, r = 0.27, P\0.001),
multiple organ dysfunction (SOFA score, r = 0.30,
P\0.001), creatinine level (r = 0.32, P\0.001), age
(r = 0.22, P = 0.002), and peak 24-h dose of dobutamine
79(r = 0.15, P = 0.03) and noradrenalin (r = 0.19,
P = 0.007). Elevated NT-proBNP levels on inclusion
(P\0.001), previous cardiovascular disease (P = 0.005),
and increased BMI levels (P = 0.015) were associated
with high levels of hs-cTnT on study inclusion, whereas
there was no signiﬁcant association with patient age,
gender, hypertension, diabetes, platelet count, eGFR
or lactate levels (Supplementary Table 2). The model of
NT-proBNP levels, previous cardiovascular disease, and
BMI explained 42% of the variance in hs-cTnT levels
(r
2 = 0.42).
Troponin T levels and in-hospital mortality
The median hs-cTnT level on inclusion in this study was
higher in hospital non-survivors than in survivors: 0.054
(Q1–3, 0.022–0.227) versus 0.035 (0.015–0.111) lg/L,
P = 0.047 (Fig. 2), while the fourth-generation assay did
not differentiate between hospital non-survivors and sur-
vivors: 0.04 (0.00–0.21) versus 0.02 (0.00–0.09) lg/L,
P = 0.14. cTnT levels after 72 h were not different for
patients surviving to hospital discharge and non-survi-
vors, either measured by the highly sensitive assay: 0.054
(0.019–0.224)versus0.035(0.015–0.093)lg/L,P = 0.054,
or by the fourth-generation assay: 0.03 (0.00–0.20) versus
0.01 (0.00–0.08) lg/L, P = 0.11. Change in cTnT levels
from inclusion in this study to 72 h was not associated
with in-hospital mortality: neither according to the high
sensitivity assay: non-survivors: 0.001 (-0.033 to 0.015)
versus survivors: -0.004 (-0.028 to 0.003) lg/L
(P = 0.63), nor the fourth-generation cTnT assay: non-
survivors: 0.00 (-0.03 to 0.02) versus survivors: 0.00
(-0.02 to 0.00) lg/L (P = 0.52). In the subgroup of
patients with moderate severity of disease (inframedian
SAPS II score\47 points, n = 97), hs-cTnT levels were
not different in hospital non-survivors (n = 15) compared
to survivors (n = 82): 0.042 (0.018–0.242) versus 0.030
(0.012–0.098) lg/L (P = 0.17). In patients with unde-
tectable cTnT levels with the fourth-generation assay on
inclusion (n = 83), no signiﬁcant differences in hs-cTnT
levels in non-survivors (n = 16) versus survivors
Table 1 Characteristics of the study patients according to in-hospital survival status
Variable Non-survivors (n = 47) Survivors (n = 160) P value
Age 65 (56–76) 58 (47–70) 0.001
Male sex 27 (57%) 114 (71%) 0.079
Body mass index 25 (23–27) 26 (23–29) 0.36
Cardiovascular disease 19 (40%) 34 (21%) 0.012
Diabetes 12 (26%) 31(19%) 0.41
Hypertension 16 (34%) 59 (37%) 0.73
Positive blood culture 12 (26%) 45 (28%) 0.85
Ventilator treatment 41 (86%) 114 (71%) 0.034
Peak creatinine levels in 24 h (lmol/L) 128 (66–275) 98 (70–159) 0.10
Lowest eGFR in 24 h (mg/min) 38 (19–92) 68 (39–99) 0.04
Peak lactate levels in 24 h (mmol/L) 2.9 (1.6–4.0) 1.9 (1.1–3.1) 0.02
Lowest platelet count in 24 h (910
9/L) 126 (87–234) 148 (88–267) 0.52
SAPS II score 51 (39–60) 41 (31–50) \0.001
SOFA score 9 (7–13) 8 (6–10) 0.013
4th gen cTnT on inclusion (lg/L) 0.04 (0.00–0.21) 0.02 (0.00–0.09) 0.14
hs-cTnT on inclusion (lg/L) 0.054 (0.022–0.227) 0.036 (0.015–0.111) 0.047
NT-proBNP on inclusion (pg/mL) 7,374 (1,308–16,917) 3,631 (1,256–9,208) 0.11
4th gen cTnT at 72 h (lg/L) 0.03 (0.00–0.20) 0.01 (0.00–0.08) 0.11
hs-cTnT at 72 h (lg/L) 0.054 (0.019–0.224) 0.035 (0.015–0.093) 0.054
NT–proBNP at 72 h (pg/mL) 5,516 (1,364–17,241) 2,231 (616–6,110) 0.03
eGFR estimated glomerular ﬁltration rate; SAPS II simpliﬁed acute physiology score II; SOFA sequential organ failure assessment score;
hs-cTnT highly sensitive assay for cardiac troponin T; NT-proBNP N-terminal pro-B type natriuretic peptide
Fig. 2 hs-cTnT levels on inclusion in this study and 72 h thereafter
in patients surviving to hospital discharge and in non-survivors. The
horizontal line within the box represents the median level, the
boundaries of the box quartiles 1–3, and the whiskers range
(maximum value restricted to 1.59 interquartile range from the
median).
#P\0.05
80(n = 67) were found: 0.017 (0.011–0.023) versus 0.014
(0.008–0.021) (P = 0.11).
By univariate logistic regression, inclusion hs-cTnT
levels (OR 1.29 [95% CI 1.03–1.60]) and levels after 72 h
(OR 1.28 [1.04–1.58]) were both associated with in-hos-
pital mortality (Table 2). AUCs for hs-cTnT on study
inclusion and after 72 h were comparable: AUC 0.588
(95% CI 0.517–0.656) vs. 0.593 (0.522–0.661). Inclusion
or 72 h cTnT measured by the fourth-generation assay
was not associated with in-hospital mortality: ORs 1.12
[95% CI 0.98–1.27] and 1.12 [0.99–1.28], respectively).
After adjustment for age, previous cardiovascular dis-
ease,eGFR,peaklactatelevels,SAPSIIandSOFAscoresin
multivariate analysis, neither hs-cTnT nor cTnT measured
by the fourth-generation assay was associated with in-hos-
pital mortality (P values 0.26 and 0.65, respectively;
Table 2).Furthermore,theadditionofcTnTmeasurementto
SAPS II score did not improve discrimination between
hospital survivors and non-survivors: AUC = 0.678 for
SAPSIIscorealone,AUC = 0.685forSAPSII plus fourth-
generation cTnT assay, and AUC = 0.684 for SAPS
II plus hs-cTnT, both P = 0.45 vs. SAPS II alone (Fig. 3).
Troponin T levels and septic shock
hs-cTnT levels on inclusion in this study were higher in
patients with septic shock during the hospitalization
compared to those without shock: 0.044 (Q1–3, 0.024–
0.171) versus 0.033 (0.012–0.103) lg/L (P = 0.03;
Fig. 4). In contrast, cTnT levels measured by the fourth-
generation assay were comparable: 0.02 (0.00–0.15)
versus 0.01 (0.00–0.09) lg/L (P = 0.10), as were NT-
proBNP levels on inclusion: 4,809 (2,064–9,782) versus
3,631 (764–12,351) pg/mL (P = 0.17; Fig. 4). The opti-
mal cut-off for hs-cTnT to predict septic shock during the
hospitalization (86% sensitivity, 33% speciﬁcity) was
Table 2 Predictors for in-hospital mortality by univariate and multivariate logistic regression analysis
Odds ratio 95% CI p
Univariate analysis
Age, per 1 year increase 1.05 1.02–1.07 0.001
Gender (female vs. male) 1.84 0.94–3.60 0.08
Body mass index, per 1 unit increase 0.98 0.91–1.05 0.52
Cardiovascular disease 2.57 1.28–5.16 0.008
Diabetes 1.43 0.67–3.06 0.36
Hypertension 0.88 0.44–1.73 0.70
Positive blood culture 0.88 0.42–1.84 0.73
eGFR, per 1 unit increase 0.59 0.37–0.92 0.02
Lactate, per 1 unit increase 1.73 1.04–2.88 0.04
Platelet count, per 1 unit increase 0.91 0.63–1.32 0.62
SAPS II score after 24 h, per 1 unit increase 1.05 1.02–1.07 \0.001
SOFA score after 24 h, per 1 unit increase 1.17 1.05–1.29 0.003
hs-cTnT on inclusion, per 1 unit increase 1.29 1.03–1.60 0.024
4th gen cTnT on inclusion, per 1 unit increase 1.12 0.98–1.27 0.10
hs-cTnT at 72 h, per 1 unit increase 1.28 1.04–1.58 0.019
4th gen cTnT at 72 h, per 1 unit increase 1.12 0.99–1.28 0.07
Multivariate analysis: ﬁnal model
SAPS II score, per 1 unit increase 1.05 1.02–1.08 0.001
eGFR estimated glomerular ﬁltration rate; hs-cTnT highly sensitive
assay for cardiac troponin T; SAPS II simpliﬁed acute physiology
score II; SOFA sequential organ failure assessment score; eGFR
estimated glomerular ﬁltration rate; hs-cTnT highly sensitive assay
for cardiac troponin T
Fig. 3 Prognostic accuracy of in-hospital mortality for SAPS II
score alone and in combination with troponin T measurements by
either the highly sensitive assay or the established fourth-generation
assay
810.014 lg/L. Cut-off points for the fourth-generation cTnT
assay and NT-proBNP on inclusion were 0.01 lg/L (58%
sensitivity, 51% speciﬁcity) and 785 pg/mL (90% sensi-
tivity, 26% speciﬁcity), respectively. In a multivariate
model adjusting for other cardiac biomarkers and infor-
mation that were available on inclusion in this study
(Supplementary Table 3), hs-cTnT greater than 0.014 lg/
L was independently associated with shock during the
hospitalization (OR 2.45 [95% CI 1.09–5.53], P = 0.03).
Discussion
The novel ﬁndings of the current study of a large cohort
of patients with severe sepsis are that (1) detectable levels
of cTnT are present in all patients according to the new
highly sensitive assay, whereas detectable levels were
observed in 60% of patients by using a conventional
assay; (2) hs-cTnT correlated with disease severity in
severe sepsis and septic shock; and (3) although hs-cTnT
levels were signiﬁcantly higher in hospital non-survivors
than in survivors, the discriminatory ability was only
modest; and (4) hs-cTnT levels may have greatest
potential in assessing risk for septic shock.
Several studies have reported an association between
troponin levels, measured by conventional assays and
short-term outcome in severe sepsis or septic shock [8, 9,
12, 13, 15, 27], whereas others have shown no relation-
ship [10, 16]. Recently, a study of a cohort of 159 patients
with bacteraemia reported that cTnI measured with a
conventional assay is a univariate, but not an independent
predictor of outcome [14]. In another study with 218
paediatric septic or septic shock patients the same pattern
was observed [28]. The current study, which to our
knowledge is the ﬁrst to evaluate the novel highly sen-
sitive assay and includes the largest cohort of adult septic
patients with troponin measurements, conﬁrms and
extends the data regarding short-term risk stratiﬁcation in
severe sepsis. Moreover, the study results suggest that hs-
cTnT measurement, despite reﬂecting cardiomyocyte
injury, does not reliably identify non-surviving patients.
Thus, although we used a highly sensitive cTnT assay,
closely associated with traditional indices of risk, and
identiﬁed low-level myocardial troponin release in a
greater proportion of patients than the traditional fourth-
generation troponin assay, this did not translate into sig-
niﬁcantly improved prediction of in-hospital mortality.
This was also the case in subgroups of patients with
intermediate risk and in the patients that had undetectable
cTnT levels as measured by the fourth-generation assay.
The lack of information regarding mortality could be
attributable to myocardial dysfunction not being the
principal mode of death in patients with severe sepsis,
thus also diminishing the merit of hs-cTnT as a marker of
mortality in sepsis. In contrast, hs-cTnT may still be of
use in patients with severe sepsis for detection of shock.
Interestingly, we found that the previously recognized hs-
cTnT 99th percentile level of 0.014 lg/L in the general
population was superior to other cardiac biomarkers and
clinical variables for prediction of shock. Thus, a cTnT
level less than 0.014 lg/L in the early stage of severe
sepsis may be useful to identify patients with low risk of
shock, which is in line with a strategy previously also
proposed for NT-proBNP [29]. Still, this result needs to
be conﬁrmed in future studies, and especially in studies
that also compare hs-cTnT measurement to echocardio-
graphic ﬁndings.
As the cardiac-speciﬁc troponins differ from skeletal
muscle-derived troponin isoforms, detection of cTnI and
cTnT in the circulation has generally been considered a
sensitive and speciﬁc marker of cardiomyocyte necrosis,
and these proteins are today routinely used in the clinical
context of acute coronary syndromes [4, 5]. Although a
low-grade elevation of circulating troponin T levels can
also be found in healthy individuals after strenuous
physical exercise [30], the association between hs-cTnT
levels and septic shock in our patients points to a role for
hs-cTnT in sepsis as an indicator of myocardial function
and circulatory status. This is also supported by a close
association between hs-cTnT and NT-proBNP levels, and
the higher hs-cTnT levels found in patients with estab-
lished cardiovascular disease. Interestingly, elevated
troponin levels have also been detected in other cardiac
and non-cardiac conditions, including acute and chronic
heart failure [31, 32], renal failure [33], chronic obstruc-
tive pulmonary disease [34, 35], pulmonary embolism
[36], and sepsis [8–16, 27, 28, 37]. The mechanism for
troponin elevation in these conditions may not be an
acute coronary artery occlusion, but rather low-grade
Fig. 4 hs-cTnT and NT-proBNP levels on inclusion in this study in
patients with circulatory failure and non-failure during the index
hospitalization. The horizontal line within the box represents the
median level, the boundaries of the box quartiles 1–3, and the
whiskers range (maximum value restricted to 1.59 interquartile
range from the median).
#P\0.05
82cardiomyocyte injury due to an unfavourable myocardial
milieu [1, 2, 37]. Still, earlier studies of patients with
sepsis have reported an association between troponin
elevation and left ventricular dysfunction, as assessed by
echocardiography and pulmonary artery catheterization
[8–10, 12]. Potential contributing factors to troponin
elevation in this setting are reduced myocardial blood
ﬂow secondary to arterial hypotension, microvascu-
lar thrombosis with subsequent myocardial injury and
augmented myocardial apoptosis secondary to pro-inﬂam-
matory cytokines, including tumour necrosis factor-a,
interleukin-1b, and interleukin-6 [1, 2]. Moreover, troponin
release in sepsis does not necessarily indicate cardiomy-
ocyte necrosis, but could also be a result of increased cell
permeability and the release of troponin degradation
products through the cell membrane in non-necrotic
cardiomyocytes [38]. The value of troponin measurement
for assessing myocardial function and cardiovascular
status is supported by our study, but it should be recog-
nized that diverging results have been reported for the
cytokine-mediated troponin release [39] and the alleged
impaired coronary blood ﬂow in patients with septic
shock [40].
Our study has some limitations. First, because of the
exclusion of early deaths patients with consent for blood
samples at both time points had slightly lower in-hospital
mortality compared to all participants in the FINNSEPSIS
study. Second, we were not able to include any objective
measures of cardiac function, such as echocardiography.
Finally, no assessment of coronary anatomy was per-
formed, thus precluding assessment of the contribution of
coronary stenosis to troponin elevation. Furthermore,
these data do not translate to any conclusions for troponin
I, as the mechanism for release and frequency of elevation
may be different. The timing of blood sampling may also
have affected the results for troponin measurement,
although our daily screening strategy ensured that a high
proportion of the samples were obtained early after start
of sepsis.
In conclusion, we found that the novel highly sensitive
assay detects circulating troponin T in all patients with
severe sepsis, and that hs-cTnT levels are correlated with
indices of poor prognosis in sepsis, but does not add to
SAPS II score for prediction of in-hospital mortality. In
contrast, hs-cTnT levels in the early phase of sepsis seem
to provide interesting information regarding shock, and
the major use of hs-cTnT measurement in sepsis could
possibly be to stratify patients regarding risk of shock.
Still, this needs to be veriﬁed in additional studies, and
also compared to objective measures of cardiac function,
as assessed by echocardiography or other imaging
modalities.
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